The pharmacokinetics of pravastatin in patients on chronic hemodialysis

European Journal of Clinical Pharmacology

Volumn 53, Issue 2, 1997, Pages 117-121

  Gehr, T W B ^a   Sica, D A ^a   Slugg, P H ^b   Hammett, J L ^b   Raymond, R ^b   Ford, N F ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Hemodialysis; Pharmacokinetics; Pravastatin

Indexed keywords

ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM CARBONATE; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIVITAMIN; PHOSPHATE BINDING AGENT; PRAVASTATIN; RECOMBINANT ERYTHROPOIETIN; SQ 31906; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOAVAILABILITY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; FEMALE; GAS CHROMATOGRAPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PRAVASTATIN; RENAL DIALYSIS;

EID: 0030825989     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050348     Document Type: Article

References (14)

1. Nakaya N, Hommo Y, Tamachi H, Shigematsu H, Hata Y, Goto Y (1987) The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. JAMA 257: 3088-3093
2. Pan HY, Willard DA, Funke PT, McKinstry DN (1987) The clinical pharmacology of SQ 31 000 (CS 514) in healthy subjects. In: Paoletti R, Kritchevsky D, Holmes WL (eds) Drugs affecting lipid metabolism. Springer Verlag, Berlin, pp 255-259
3. Furberg CD, Bertram P, Byington RP, Jong-Soon P, Mcgovern ME, for the PLAC I and PLAC II Investigators (1995) Reduction in coronary events during treatment with pravastatin. Am J Cardiol 76: 60C-63C
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia N Engl J Med 333: 1302-1307
5. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. Drua Metah Disp 19: 740-748
6. Pan HY, Funke PT, Willard DA, McKinstry DN (1989) Pharmacokinetics, pharmacodynamics and safety of pravastatin sodium, a potent inhibitor of HMG0CoA reductase, in healthy volunteers. In: LaRose JC, (ed) New advances in the control of lipid metabolism: focus on pravastatin. Royal Society of Medicine Services, London, pp 9-21
7. Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H (1992) Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 32: 124-132
8. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG (1983) Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48: 279-288
9. Farmen RH, Muniak JF, Pittman KA (1987) Management of pharmacokinetic data using HP-3357/Mainframe IBM interfacing. Drug Information J 21: 141-152
10. Gibaldi M, Perrier D (1988) In: Welling PG, Tse FLS (eds) Pharmacokinetics, 2nd edn, Dekker, New York, pp 409-417
11. Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8: 509-534
12. Gibson TP, Nelson HA (1977) Drug kinetics and artificial kidneys. Clin Phamacokinet 2: 403-426
13. Funke PT, Ivashkiv E, Arnold ME, Cohen AI (1989) Determination of pravastatin sodium and its major metabolites in human serum plasma by capillary gas chromatography negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom 18: 904-909
14. Querin S, Lambert R, Cusson JR, Gregoire S, Vickers S, Stubbs RJ, Sweany AE, Larochelle P (1991) Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 50: 437-441